Compare Bill.com Holdings Inc (BILL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs BioNano Genomics Inc — how do they compare? Bill.com Holdings Inc trades at $48.13 (market cap $4.93B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Bill.com Holdings Inc is far larger — about 360.9× BioNano Genomics Inc's market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BILL | BNGO | |
|---|---|---|
Market Cap | $4.93B | $13.66M |
Sector | Technology | Health |
52-Week High | $56.32 | $4.92 |
52-Week Low | $31.96 | $1.06 |
Enterprise Value | $4.64B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.37, down 1.81% today, with a bullish technical signal and strong analyst support (56% buy ratings). The company shows improving fundamentals with revenue growth to $1.46B in 2025 and three consecutive quarterly EPS beats, though profitability remains thin with a net margin of 0.01%. Recent news highlights AI-driven strategy and operational efficiency gains.
Outlook is cautiously optimistic given earnings momentum and institutional accumulation, but high valuation (P/E 213.91) and negative cash flow from investing pose risks. Upside to consensus price target $45.67 appears limited at current levels, requiring sustained execution for further gains.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
